CDKN2B-AS1 and cancer: Analysis showed that high expression of ANRIL was significantly associated with shorter OS in patients with cancers of the digestive system (HR = 2.02, 95% CI: 1.62–2.52, P < 0.00001) and non-digestive systems (HR = 2.31, 95% CI: 1.72–3.10, P < 0.00001).